Alentis Appoints Jonathan Freve CFO Post published:September 3, 2024 Continue ReadingAlentis Appoints Jonathan Freve CFO
Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis Post published:May 29, 2024 Continue ReadingAlentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis
Alentis Announces Presentations on Claudin-1 in Fibrosis at the ERA and ATS Conferences Post published:May 14, 2024 Continue ReadingAlentis Announces Presentations on Claudin-1 in Fibrosis at the ERA and ATS Conferences
Alentis Sponsors 3rd International Summit on Lung Cancer Post published:May 2, 2024 Continue ReadingAlentis Sponsors 3rd International Summit on Lung Cancer
Alentis Appoints Alberto Toso Chief Scientific Officer Post published:April 29, 2024 Continue ReadingAlentis Appoints Alberto Toso Chief Scientific Officer
Alentis ´Shares Their Colors´ for Rare Disease Day 2024 Post published:February 29, 2024 Continue ReadingAlentis ´Shares Their Colors´ for Rare Disease Day 2024
William Pao Joins Alentis Therapeutics as Independent Board Member Post published:January 8, 2024 Continue ReadingWilliam Pao Joins Alentis Therapeutics as Independent Board Member
Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer Post published:December 6, 2023 Continue ReadingAlentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer
Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02) Post published:December 5, 2023 Continue ReadingAlentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Post published:November 16, 2023 Continue ReadingAlentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
